Search PubMed⌕ Search

Biomedical subjects

U Jonas

Publications and source records attributed to U Jonas.

At least 235 records · Page 13Linked to original sources
PubMed1989

Oestrogen in the treatment of prostatic carcinoma. What is the safe and effective dose of ethinyloestradiol?

The treatment of prostatic carcinoma with diethylstilboestrol (DES) and ethinyloestradiol (Lynoral) has become less popular since the introduction of new forms of treatment such as antiandrogens, estramustine phosphate and LHRH analogues. One of the reasons for this decline in popularity is the risk of cardiovascular side effects during treatment with oestrogens. In the literature, different dosages of DES and ethinyloestradiol are recommended and different rates of cardiovascular side effects are reported. In a prospective study, 18 patients were treated with ethinyloestradiol 0.05 mg/day. In most cases this lowered the plasma testosterone permanently below castrate level during therapy. Also, because the acid phosphatase returned to normal in almost all patients, this treatment seemed adequate. In 4 patients the treatment was stopped because of side effects, in 3 of these because of cardiovascular complications. The cardiovascular side effect at this dose are considerable (29%) but comparable rates are reported in some studies following placebo treatment of patients with prostatic carcinoma.

Aged↗
PubMed1988

Perfusion of tumor-bearing kidneys as a model for scintigraphic screening of monoclonal antibodies.

Tumor-bearing human kidneys were used in an ex vivo perfusion model to screen monoclonal antibodies, recognizing renal cell carcinoma-associated antigens for diagnostic potential in vivo. Perfusion of tumor-bearing kidneys with 99mTc-labeled G250 and RC38 antibody resulted in visualization of the tumor, whereas perfusion with two other monoclonal antibodies, RC2 and RC4, did not lead to tumor visualization. Uptake of radiolabel in normal kidney tissue was low for G250 and RC38 antibody. Tumor-to-kidney tissue ratios after perfusion with G250 and RC38 antibody were 2.7 and 2.2, respectively. After rinsing for 3 hr with unlabeled perfusion fluid the tumor-to-kidney tissue ratios increased to 8.6 for G250 antibody and to 2.7 for RC38 antibody. We conclude that perfusion of tumor-bearing human kidneys with radiolabeled monoclonal antibodies is a relatively simple way to evaluate renal cell carcinoma associated monoclonal antibodies as diagnostic agents in vivo.

Antibodies, Monoclonal↗
PubMed1987

The determination of relative kidney function in obstructive uropathy with 99Tcm-DMSA.

In this investigation differential kidney function studies were carried out for eight patients with obstructive uropathy and seven patients who did not suffer from obstruction. The aim of this investigation was to determine whether possible retention of 99Tcm-DMSA in the dilated system would lead to overestimation of the functional mass of an obstructed kidney. The clinical examination took place 4 and 24 h after i.v. injection of the 99Tcm-DMSA. From our results we conclude that this is not a major problem. It appeared that the 4 h values are as reliable as the 24 h values in the clinical situation.

Humans↗
PubMed1987

[Modern urodynamics].

Explore the source record for details and available documents.

Diagnosis, Computer-Assisted↗
PubMed1986

Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney.

This report describes a monoclonal antibody designated G 250, subclass IgGl, that recognizes an antigen preferentially expressed on cell membranes of renal-cell carcinoma cells (RCC) and not expressed in normal proximal tubular epithelium. G 250 antibody reacted with 46 of 47 primary RCC, with 7 of 8 RCC metastases and with a few other malignant tumors. The staining pattern of G 250 differs from that of other RCC-related antibodies described. Preliminary experiments show that this antibody can be used to visualize RCC xenografts in nude mice by immunoscintigraphy.

Animals↗
PubMed1986

Immunohistochemical analysis of monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell carcinoma.

Four mouse monoclonal antibodies reacting with renal proximal epithelium were characterized on normal adult tissues, fetal kidneys, and various malignancies. These four antibodies were found to react with renal cell carcinomas (RCCs) but not with a variety of other tumors. Three antibodies react only with some primary RCCs and not with metastatic RCCs. The fourth antibody, RC 38, reacts with 46 of 47 primary RCCs tested and with 8 of 13 RCC metastases. No reaction was seen with 179 tumors of various origin, which indicates that this antibody is very useful in diagnosing RCC.

Adenoma↗
PubMed1986

[Automated uroflowmetry: new variables].

In a major uroflow study new variables are introduced to meet the needs, and to use the possibilities of automatic processing of uroflow signals. It is found that the new variables provide excellent discrimination between male and female patients with bladder outflow impairment and healthy controls. In comparison to some conventional variables they have the advantage of unambiguous determination and low sensitivity to random measurement errors.

Computers↗
PubMed1984

[Conservative therapy of phosphate calculi].

Phosphate stones are divided in two groups: I. Infection stones = triple phosphate stones (struvite and carbonate apatite). II. Calcium phosphate stones = Hydroxy apatite. Ad I. For the formation of this stone, infection with urease-producing bacteria is essential. It is important to look for factors that cause infection and for metabolic abnormalities. Three possibilities for treatment are discussed: Acidifying the urine: orally with NH4NO3 or NH4Cl; dosage is possible up to 12 g a day (metabolic acidosis!). Irrigation for instance with Renacidin ; when using a nephrostomy-tube, one can start 5 days after the operation. It is important to look for fever and flank pain. Especially useful in cases with small residual stones. Reduction of phosphate excretion in urine ( Shorr -regimen). Some aluminium combinations reduce the intestinal phosphate absorption as a result of the formation of a nonabsorbable aluminium-phosphate combination. This can be combined with a low calcium- and phosphate diet. In several publications good results are shown. Also when using a less rigid regimen, satisfactory results are seen: decrease of the phosphate excretion from 30 to 17 mmol/24 h (own investigation). Urease-inhibitors result in a lower urine-pH and a decrease of the ammonium-concentration. there are only a few publications with results, but AHA seems able to reduce the stone size in 24% of the patients. Ad II. This stone is concerning formation and treatment much like the calcium oxalate stone. In case of an alkaline urine one must look for primary hyperparathyroidism and renal tubular acidosis.(ABSTRACT TRUNCATED AT 250 WORDS)

Anti-Bacterial Agents↗
PubMed1982

[Impotence].

Explore the source record for details and available documents.

Erectile Dysfunction↗
PubMed1982

Further experiences with the stereoresectoscope: description and clinical use.

A binocular stereoresectoscope with a variable ocular distance between 60 and 73 mm., and an objective distance of 2.65 mm. is reported. A transmission factor of 25 leads to an excellent stereoscopic effect. Since it has an outer diameter of 25F this instrument fits the usual norm of resectoscopes. The resection sling revolves around 320 degrees and both oculars, as well as the movements made during resections, remain in a more or less similar plane. Further clinical experience shows that as the physician becomes accustomed to the use of this instrument fusion of the 2 images becomes easier. The ease of orientation afforded by the stereoscopic effect aids in the resection. Despite the complexity of the instrument the resectoscope remains simple to use.

Humans↗